Speech and voice are multidimensional signals that capture both communicative intent and underlying physiological processes, providing a unique, non-invasive window into health. Analyzing these signals has the potential to yield digital biomarkers that (i) provide scalable, objective measurement tools for research and clinical care and (ii) reflect the presence or progression of diverse conditions, including neurological, psychiatric, respiratory, and cardiovascular disorders. Realizing this promise, however, requires the field to overcome pervasive reproducibility and generalizability issues due to heterogeneous data collection, processing, and analysis practices. A major source of this heterogeneity is how underlying acoustic measures themselves are defined and computed. In this paper, we outline key considerations across the speech biomarker discovery lifecycle, from data collection through machine learning modeling to clinical interpretation, needed to achieve reliable, reproducible, and clinically translatable results. Chief among these is the need for harmonization efforts to start from common, precisely specified measure definitions. As a first step, we therefore provide definitions, physiological correlates, and computational implementations for a minimal, clinically interpretable set of core speech measures spanning respiration, phonation, articulation, and fluency. We close by discussing ongoing standardization efforts and the open challenges that remain in advancing the adoption of speech- and voice-based digital biomarkers.

翻译：暂无翻译